The secondary outcome was to compare the measurements of TAS, total oxidant status (TOS), ischemia-modified albumin (IMA) level, and catalase (CAT) level before ischemia onset (t1) and at the t2 and t3 time points. The gene discussed is ALB; the disease is ischemia.